Clinical Trials Sponsored by Astellas Pharma China, Inc

Total 1223 results

Ophthotech Corporation

Completed

ARC1905 (ANTI-C5 APTAMER) Given Either In Combination Therapy With Lucentis® 0.5 mg/Eye In Subjects With Neovascular Age-Related Macular Degeneration

Age-Related Macular Degeneration

United States
Ophthotech Corporation

Withdrawn

ZIMURA in Combination With Eylea in Patients With Idiopathic Polypoidal Choroidal Vasculopathy (IPCV)

Idiopathic Polypoidal Choroidal Vasculopathy

United States
Ophthotech Corporation

Completed

A Study of ARC1905 (Anti-C5 Aptamer) in Subjects With Dry Age-related Macular Degeneration

Age-Related Macular Degeneration

United States
FibroGen
AstraZeneca; Astellas Pharma Inc

Completed

Evaluation of Efficacy and Safety of Roxadustat for the Treatment of Chemotherapy Induced Anemia

Chemotherapy Induced Anemia

United States
OSI Pharmaceuticals

Completed

Erlotinib, Gemcitabine and Nab-Paclitaxel in Advanced Pancreatic Cancer

Advanced Pancreatic Cancer

United States
OSI Pharmaceuticals

Completed

Erlotinib (Tarceva (Trademark), OSI-774) in Treating Patients With Advanced Non-Small Cell Lung Cancer

Advanced Non Small Cell Lung Cancer | Failed Prior Chemotherapy

United States
Tufts University
Astellas Pharma Inc

Completed

Resistance Training in Older Adults With Limitations in Mobility (TRANS2)

Mobility Limitation
Heidelberg University
Astellas Pharma Inc

Unknown

Delayed CNI-based Immunosuppression With Advagraf After MELD-based Liver Transplantation (IMUTECT)

Liver Graft Dysfunction

Germany
Astellas Pharma Inc
Schering-Plough

Completed

Comparison in Efficacy and Safety Between Interferon Alfacon-1 Alone and Concomitant Dosing With Ribavirin for the Treatment of Hepatitis C

Hepatitis C

Japan
Mayo Clinic
Astellas Pharma Inc

Completed

Myocardial Blood Flow by PET and N-13 Ammonia During Regadenoson vs Adenosine Stress

Coronary Artery Disease

United States
Northwestern University
Astellas Pharma Inc

Terminated

A Pilot Study to Assess the Safety and Efficacy of Alefacept in de Novo Kidney Transplant Recipients

Transplant; Failure, Kidney

United States
Astellas Pharma Inc
OSI Pharmaceuticals

Completed

A Phase III Study of the Efficacy of Taxotere/Aptosyn Versus Taxotere/Placebo in Non-Small Cell Lung Cancer Patients

Non-Small Cell Lung Cancer

United States
Astellas Pharma Inc
OSI Pharmaceuticals

Completed

Phase II Study of Taxotere in Combination With Exisulind in Non-Small Cell Lung Cancer (NSCLC) Patients

NSCLC

United States
Astellas Pharma Inc
OSI Pharmaceuticals

Completed

A Pilot Study of OSI-461 in Patients With Chronic Lymphocytic Leukemia (CLL)

Chronic Lymphocytic Leukemia

United States
Astellas Pharma Inc
OSI Pharmaceuticals

Completed

Phase I Study of OSI-930 and Erlotinib in Cancer Tumors

Advanced Solid Tumors

United States, United Kingdom
Astellas Pharma Inc
Basilea Pharmaceutica

Completed

Drug Interaction Study of Isavuconazole and Midazolam

Healthy Volunteers | Pharmacokinetics of Isavuconazole | Pharmacokinetics of Midazolam

United States
Astellas Pharma Global Development, Inc.
Kyowa Kirin Co., Ltd.

Completed

A Multiple Dose Escalation Study of ASKP1240 in Subjects With Moderate to Severe Plaque Psoriasis

Psoriasis

Canada, Australia, New Zealand
Astellas Pharma Global Development, Inc.
Merck Sharp & Dohme LLC

Completed

A Multiple-dose Study of ASP8374, an Immune Checkpoint Inhibitor, as a Single Agent and in Combination With Pembrolizumab in Subjects With Advanced Solid Tumors

Advanced Solid Tumors

United States, Korea, Republic of, Taiwan, Portugal, Spain, United Kingdom, Italy, Canada, Japan
Astellas Pharma Global Development, Inc.
Basilea Pharmaceutica International Ltd

Completed

Study of the Pharmacokinetics of Isavuconazole in Healthy Non-Elderly and Elderly Male and Female Subjects

Healthy Volunteers | Pharmacokinetics of Isavuconazole | Safety and Tolerability in Elderly

United States
Astellas Pharma Global Development, Inc.
Basilea Pharmaceutica International Ltd

Completed

Drug Interaction Study of Isavuconazole and Digoxin

Healthy Volunteers | Pharmacokinetics of Isavuconazole | Pharmacokinetics of Digoxin

United States
Astellas Pharma Global Development, Inc.
Basilea Pharmaceutica International Ltd

Completed

Drug Interaction Study of the Effect of Ketoconazole at Steady State on the Pharmacokinetics of a Single Dose of Isavuconazole in Healthy Adult Subjects

Healthy Adult Volunteers | Pharmacokinetics of Isavuconazole | Pharmacokinetics of Ketoconazole

United States
Astellas Pharma Global Development, Inc.
Basilea Pharmaceutica International Ltd

Completed

Drug Interaction Study of Multiple Doses of Isavuconazole and a Single Dose of Bupropion

Healthy Volunteers | Pharmacokinetics of Isavuconazole | Pharmacokinetics of Bupropion

United States
Astellas Pharma Global Development, Inc.
Basilea Pharmaceutica International Ltd

Completed

Drug Interaction Study of Multiple Doses of Isavuconazole and Single Dose of Dextromethorphan in Healthy Adult Subjects

Healthy Adult Volunteers | Pharmacokinetics of Isavuconazole | Pharmacokinetics of Dextromethorphan

United States
Astellas Pharma Global Development, Inc.
Basilea Pharmaceutica International Ltd

Completed

Drug-drug Interaction Study Between Lopinavir/Ritonavir and Isavuconazole

Healthy Volunteers | Pharmacokinetics of Isavuconazole | Pharmacokinetics of Lopinavir/Ritonavir

United States
Astellas Pharma Global Development, Inc.
Basilea Pharmaceutica International Ltd

Completed

A Study to Evaluate the Effect of Multiple Doses of Esomeprazole on the Pharmacokinetics of Isavuconazole

Healthy Subjects | Pharmacokinetics of Isavuconazole

United States
Astellas Pharma Global Development, Inc.
Basilea Pharmaceutica International Ltd

Completed

A Study to Evaluate the Pharmacokinetics of BAL8728 After a Single Dose of Pyridinylmethyl-14C-Labeled Isavuconazonium Sulfate in Healthy Male Subjects

Healthy Subjects | Pharmacokinetics of 14C-labeled Isavuconazonium Sulfate

United States
Astellas Pharma Global Development, Inc.
Basilea Pharmaceutica International Ltd

Completed

Study to Evaluate the Pharmacokinetics of 14C-labeled Isavuconazole Following a Single Oral Dose of 14C-labeled Prodrug Isavuconazonium Sulfate (BAL8557) in Healthy Male Subjects

Healthy Subjects | Pharmacokinetics of 14C-labeled Isavuconazole

United States
Astellas Pharma Global Development, Inc.
Basilea Pharmaceutica International Ltd

Completed

A Study to Evaluate the Effect of Multiple Doses of Isavuconazole on the Pharmacokinetics of a Single Dose of Sirolimus in Healthy Subjects

Healthy Subjects | Pharmacokinetics of Isavuconazole | Pharmacokinetics of Sirolimus

United States
Astellas Pharma Global Development, Inc.
Kyowa Kirin Co., Ltd.

Completed

Study of ASKP1240 After a Single Intravenous Dose at Escalating Dose Levels in Healthy Subjects

Healthy Volunteers | Pharmacokinetics of ASKP1240

United States
FibroGen
AstraZeneca; Astellas Pharma Inc

Terminated

Efficacy and Safety of Roxadustat for Treatment of Anemia in Participants With Lower Risk Myelodysplastic Syndrome With Low Red Blood Cell Transfusion Burden

Primary MDS (Very Low, Low or Intermediate IPSS-R With <5% Blasts)

United States, Australia, Belgium, Germany, Israel, Italy, Korea, Republic of, Russian Federation, Spain, United Kingdom, France, Turkey, Canada, Denmark, India, Poland
Ophthotech Corporation

Terminated

A Phase 3 Safety and Efficacy Study of Fovista® (E10030) Intravitreous Administration in Combination With Either Avastin® or Eylea® Compared to Avastin® or Eylea® Monotherapy

Age-Related Macular Degeneration

France, Israel, Italy, United States, Spain, Portugal, Germany, Austria, Canada, Czechia, Estonia, Latvia, Poland, Slovakia, Australia, Hungary, Croatia, Argentina, Finland, Brazil, Colombia, Norway
Ophthotech Corporation

Terminated

A 24 Month Phase 2a Open Label, Randomized Study of Avastin®, Lucentis®, or Eylea® (Anti-VEGF Therapy) Administered in Combination With Fovista® (Anti-PDGF BB Pegylated Aptamer)

Age-Related Macular Degeneration

United States
PrECOG, LLC.
Astellas Pharma Inc

Active, not recruiting

Gilteritinib vs Midostaurin in FLT3 Mutated Acute Myeloid Leukemia

Acute Myeloid Leukemia

United States
Ophthotech Corporation

Completed

A Phase 1 Ascending and Parallel Group Trial to Establish the Safety, Tolerability and Pharmacokinetics Profile of Volociximab (Alpha 5 Beta 1 Integrin Antagonist) in Subjects With Neovascular Age- Related Macular Degeneration

Age-related Macular Degeneration
OSI Pharmaceuticals

Terminated

Erlotinib Versus Oral Etoposide in Patients With Recurrent or Refractory Pediatric Ependymoma (PETEY)

Recurrent or Refractory Pediatric Ependymoma

United States, Canada, United Kingdom
OSI Pharmaceuticals

Terminated

Single-agent Erlotinib in Patients Previously Treated With Oral Etoposide in Protocol OSI-774-205

Ependymoma

United States, Canada, United Kingdom
Astellas Pharma Inc
Basilea Pharmaceutica

Completed

Isavuconazole (BAL8557) in the Treatment of Candidemia and Other Invasive Candida Infections

Mycoses | Candidemia | Candidiasis, Invasive

Philippines, New Zealand, United States, Spain, Belgium, Canada, Israel, Malaysia, Mexico, Italy, Australia, Germany, Singapore, Hungary, Brazil, Thailand, China, India, Argentina, France, Russian Federation, Chile, Lebanon, South Africa and more
OSI Pharmaceuticals

Completed

A Pharmacokinetic Study of Erlotinib in Cancer Patients With Advanced Solid Tumors, With Adequate and Moderately Impaired Hepatic Function

Advanced Solid Tumors

United States, United Kingdom
Columbia University
Astellas Pharma Inc

Withdrawn

Safety and Efficacy of Conivaptan for the Correction of Hyponatremia in Neurological Patients

Hyponatremia

United States
Mahidol University
Astellas Pharma Inc

Unknown

Impact of CYP3A5 Gene Polymorphisms on Tacrolimus Concentrations and Outcomes in Thai Transplant Recipients

Kidney Transplant
Boehringer Ingelheim
Astellas Pharma Inc

Completed

Post-Marketing Surveillance of Micombi Tablets Survey on the Long-term Use

Hypertension

Japan
MDDX LLC
Astellas Pharma Inc

Withdrawn

Registry for CARDIAC PERFUSION CT (RECRUIT)

Coronary Artery Disease

United States
Hartford Hospital
Astellas Pharma Inc

Terminated

Clinical Trial of Solifenacin Versus Placebo Plus Pessary for Women With Vaginal Prolapse (PESSARY)

Pelvic Organ Prolapse

United States
Pfizer
Astellas Pharma Inc; Medivation, Inc.

Active, not recruiting

Efficacy and Safety Study of Enzalutamide in Combination With Exemestane in Patients With Advanced Breast Cancer

Breast Cancer

United States, Spain, Belgium, Canada, Italy, Ireland, United Kingdom
AbbVie
Astellas Pharma Inc; Genentech, Inc.

Completed

A Study to Assess Safety and Efficacy of Venetoclax in Combination With Gilteritinib in Participants With Relapsed/Refractory Acute Myeloid Leukemia

Acute Myeloid Leukemia (AML)

United States
AVEO Pharmaceuticals, Inc.
Astellas Pharma Inc

Terminated

A Subject Treatment Preference Study of Tivozanib Versus Sunitinib in Subjects With Metastatic RCC (TAURUS)

Metastatic Renal Cell Carcinoma

France, United Kingdom, Germany, Spain, Belgium, United States, Italy
AVEO Pharmaceuticals, Inc.
Astellas Pharma Inc

Terminated

Tivozanib in Combination With Paclitaxel in Patients With Locally Recurrent or Metastatic Triple Negative Breast Cancer (BATON-BC)

Triple Negative Breast Cancer

Germany, Taiwan, Spain, Ukraine, Australia, Korea, Republic of, Canada, United States, Italy, Bahamas
Astellas Pharma Inc
Immunomic Therapeutics, Inc.

Completed

A Dose-finding Study of ASP4070

Rhinitis, Allergic, Seasonal

Japan
Astellas Pharma Inc
Ajinomoto USA, INC.

Completed

Nateglinide: a Double Blind Add-on Study With Pioglitazone for Type 2 Diabetic Patients

Type 2 Diabetes Mellitus | Diabetes Mellitus, Type II

Japan
Propella Therapeutics

Recruiting

Open-label, Multicenter Study of Intramuscular PRL-02 Depot in Patients With Advanced Prostate Cancer

Prostate Cancer | mCRPC | mCSPC

United States

Clinical Trials Sponsored by Astellas Pharma China, Inc

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Armenia

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations